Background. Hypervolemic hypernatremia is caused by an increase in total exchangeable Na + and K + in excess of an increment in total body H 2 O (TBW). Unlike patients with hypovolemic or euvolemic hypernatremia, treatment needs to be targeted at correcting not only the elevated plasma Na + concentration, but also there is an additional requirement to achieve negative H 2 O balance to correct the increment in TBW. Methods. Correction of hypervolemic hypernatremia can be attained by ensuring that the negative Na + and K + balance exceeds the negative H 2 O balance. These seemingly conflicting therapeutic goals are typically approached by administering intravenous 5% Dextrose (IV D5W) and furosemide.
concentration, but also there is an additional requirement to achieve negative H 2 O balance to correct the increment in TBW. Methods. Correction of hypervolemic hypernatremia can be attained by ensuring that the negative Na + and K + balance exceeds the negative H 2 O balance. These seemingly conflicting therapeutic goals are typically approached by administering intravenous 5% Dextrose (IV D5W) and furosemide.
Results. Currently, there is no quantitative approach to predicting the volume of IV D5W (V IVF ) that needs to be administered that satisfies these requirements. Therefore, based on the principle of mass balance and the empirical relationship between exchangeable Na + , K + , TBW, and the plasma Na + concentration, we have derived a new equation which calculates the volume of IV D5W (V IVF ) needed to lower the plasma Na + concentration ( 
Introduction
Hypernatraemia is a common electrolyte disorder in hospitalized patients [1] . It is a disorder characterized by either an absolute or relative free water deficit. In hypovolaemic or euvolaemic hypernatraemia, there is an absolute free water deficit characterized by the negative mass balance of H 2 O (V MB ) ( Table 1) [2] . Therefore, treatment of these clinical disorders is targeted at replacement of the free water deficit with hypotonic intravenous fluids. In contrast, hypervolaemic hypernatraemia is caused by an increase in total exchangeable Na + and K + in excess of the increment in total body water (TBW), resulting in a relative free water deficit [2] . Although these patients are hypervolaemic, they have a relative free water deficit because they develop a positive mass balance of Na + and K + (E MB ) in excess of the positive mass balance of H 2 O (V MB ). Since these patients are hypervolaemic and hypernatraemic, treatment of these patients should be targeted at both the correction of the hypernatraemia and the attainment of a negative H 2 O balance. Toward this goal, intravenous 5% dextrose (IV D5W) and furosemide can be utilized to correct the hypernatraemia as well as to achieve negative H 2 
Since IV D5W is the infusate used to correct hypervolaemic hypernatraemia, [E] IVF = 0 and
Rearranging Equation 3,
Rearranging Equation 4,
In patients with euglycaemia, Equation 5 can be simplified as follows:
Discussion
The mechanisms underlying the generation of hypernatraemia can be characterized according to the mass balance of Na + and K + (E MB ) in relation to the mass balance of H 2 O (V MB ) ( Table 1 ) [2] . In hypovolaemic hypernatraemia, the negative V MB is the cause of the hypernatraemia, whereas the negative E MB in this setting would lower the [Na + ] p , but its depressive effect is less than the incremental effect of the negative V MB on the [Na + ] p . In these patients, a defect in the thirst mechanism or inadequate access to H 2 O contributes to the negative V MB . In euvolemic hypernatraemia, the negative V MB is also the cause of the hypernatraemia, and E MB is negligible in these patients. Although these patients actually have a negative V MB , they appear clinically euvolaemic because only a small fraction of the total water loss originates from the intravascular space due the negligible E MB . In contrast, in hypervolaemic hypernatraemia, it is the positive E MB that is the cause of the hypernatraemia (rather than negative V MB ); the positive V MB in these patients would tend to lower the [Na + ] p but is not of sufficient magnitude to prevent the [Na + ] p from increasing. In this setting, the compensatory V MB is inadequate due to a defect in the thirst mechanism or inadequate access to H 2 O.
Hypervolaemic hypernatraemia is therefore caused by an increase in total exchangeable Na + and K + in excess of the increment in TBW, resulting in a relative free water deficit [2] . Treatment of hypervolaemic hypernatraemia can be therapeutically challenging since the infusion of IV D5W alone will correct the hypernatraemia at the expense of worsening volume overload, whereas the administration of furosemide alone will treat the hypervolaemia at the expense of worsening hypernatraemia due to the urinary excretion of H 2 O in excess of Na + and K + . Consequently, treatment of hypervolaemic hypernatraemia needs to be targeted at correcting not only the elevated [Na + ] p , but also, there is an additional requirement to achieve a negative H 2 O balance to correct the increment in TBW. These seemingly conflicting therapeutic goals are typically approached by administering intravenous D5W (IV D5W) and furosemide to correct the hypernatraemia as well as to achieve negative H 2 O balance. Currently, there is no quantitative approach to predicting the volume of IV D5W (V IVF ) that needs to be administered that satisfies these requirements. Therefore, based on the principle of mass balance and the empirical relationship between exchangeable Na (Figure 1 ).
Clinical utility of Equation 5
The utility of Equation 5A can be demonstrated in the following clinical case example: a 92-year-old Caucasian female with a history of congestive heart failure (CHF) secondary to diastolic dysfunction (ejection fraction 65%), hypertension and paroxysmal atrial fibrillation was admitted with recurrent symptoms of CHF. The patient reported four days of shortness of breath, orthopnea, paroxysmal nocturnal dyspnea and increasing lower extremity oedema. Physical examination is significant for jugular venous pressure ∼12 cm, bibasilar crackles and 2+ peripheral oedema. The patient was aggressively diuresed with intravenous furosemide. On Day 4 of her admission, she was noted to have a [Na + ] p = 150 mmol/L; however, she remained symptomatic with her CHF, and chest X-ray revealed cardiomegaly and persistent pulmonary oedema and interstitial hydrostatic pulmonary oedema with small bilateral pleural effusions.
The renal service was consulted to help guide the management of the hypernatraemia in the setting of persistent pulmonary oedema. The patient's hypernatraemia was thought to be secondary to inadequate free H 2 O replacement in the setting of hypotonic urinary losses resulting from the aggressive diuresis. Since the patient was both hypernatraemic and hypervolaemic, intravenous D5W (IV D5W) was administered to correct the hypernatraemia and furosemide was continued to achieve the negative H 2 O balance. Importantly, the goal of therapy was to administer the required volume of IV D5W (V IVF ) needed to lower the [Na + ] p from 150 mmol/L to 140 mmol/L while achieving the targeted 2 L of negative H 2 O balance:
Parameters entered into Equation 5A: 
Therefore:
Na e1 + K e1 = (150 +23.8) × 30/1.03 = 5062 mmol Na e2 + K e2 = Na e1 
Etiologies of hypervolaemic hypernatraemia
Hypervolaemic hypernatraemia is typically iatrogenic in etiology. Hypervolaemic hypernatraemia is often induced by the administration of hypertonic sodium-containing solutions. Examples include massive ingestion of a highly concentrated saline emetic or gargle, accidental or nonaccidental salt poisoning in infants and young children and the infusion of hypertonic sodium bicarbonate to treat metabolic acidosis [6] [7] [8] . More commonly, hypervolaemic hypernatraemia is induced by the inappropriate replacement of hyponatric fluid losses with an infusate containing a higher sodium concentration [9] . Indeed, Kahn reported that hypervolaemic hypernatraemia often results from the replacement of hyponatric fluid losses (hyponatric fluid losses via sweat, gastric aspiration, diarrhea and diuretics) with isotonic saline in subjects with salt-retaining states [9] . In all these clinical scenarios, treatment of the hypervolaemic hypernatraemia necessitates the induction of a negative Na + and K + balance in excess of the negative H 2 O balance in order to ameliorate both the hypernatraemia and the hypervolaemic state.
Hyperglycaemic states
In the setting of hyperglycaemia, Equation 5 must be utilized instead of Equation 5A to guide the treatment of hypervolaemic hypernatraemia. It is well known that there is an expected decrease of 1.6 mmol/L in the plasma [Na + ] for each 100 mg/dL increment in the plasma glucose concentration resulting from the dilutional effect of hyperglycaemia induced by the translocation of water [10] . Therefore, in hyperglycaemic states, the severity of the hypernatraemia is often unrecognized due to the dilutional effect of hyperglycaemia on the plasma [Na + ]. In this setting, the severity of the hypernatraemia is often unmasked with correction of the hyperglycaemia.
Importantly, we have previously demonstrated that the y-intercept in Equation 6 is not constant and will vary predictably with the plasma glucose concentration [2, 4, 5] . Moreover, we have previously shown [2, 4, 5] 
Equation 5, therefore takes into consideration the dilutional effect of hyperglycaemia on the plasma [Na + ] by accounting for the fact that the y-intercept, y = 23.8 + (1.6/100)([G] −120), is not constant and will vary predictably with the plasma glucose concentration [2, 4, 5] .
In hyperglycaemia, the glucosuria-induced osmotic diuresis will also lead to the urinary excretion of H 2 O in excess of Na + + K + , resulting in increased urinary electrolyte-free water excretion [11] . The increased urinary electrolyte-free water excretion induced by glucosuria will in turn lead to exacerbation of the underlying hypernatraemia. In diabetic patients, oral water replacement may therefore be preferable to IV D5W to avoid hyperglycaemia. However, in patients who are on bowel rest (NPO), IV D5W can be used with close monitoring of the plasma glucose concentration and tight control of the diabetes.
Limitations of Equation 5
There are limitations that one has to take into account when using Equation 5. First, one must take into consideration the fact that there may be dynamic changes in the mass balance of Na + , K + and H 2 O during treatment. Therefore, the patient's input and output of Na + , K + , H 2 O and the plasma [Na + ] must be monitored frequently to guide further adjustments in the fluid prescription. The frequency with which this needs to be done will be determined by the clinical course and constancy of input and output sources in a given patient. Finally, the accuracy of Equation 5 is dependent on an accurate estimate of the TBW. In this regard, the regression equations reported by Watson et al. can be used to provide an accurate estimate of TBW [12] .
Conclusion
In summary, hypervolaemic hypernatraemia is caused by an increase in total exchangeable Na + and K + in excess of the increment in TBW, resulting in a relative free water deficit. Since these patients are hypernatraemic and hypervolaemic, treatment needs to be targeted at correcting not only the hypernatraemia but also to achieve a negative H 2 O balance to correct the increment in TBW. In this setting, both intravenous D5W (IV D5W) and furosemide are administered to correct the hypernatraemia and to achieve a negative H 2 O balance. Therefore, correction of hypervolaemic hypernatraemia can be attained by ensuring that the negative Na + and K + balance exceeds the negative H 2 O balance. In this article, we derived a new equation to predict the volume of IV D5W (V IVF ) that needs to be administered that satisfies these requirements. This new equation is the first quantitative approach for correcting hypervolaemic hypernatraemia by achieving negative Na + and K + balance in excess of negative H 2 O balance. This new equation should be especially helpful in providing the clinician with a quantitative approach to the correction of this common disorder.
